Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Trial Profile

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Binge-eating disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire Pharmaceuticals
  • Most Recent Events

    • 22 Jul 2015 Based on the results of this trial, as well as findings from other study (see profile 224561), the Company plans to submit a sNDA to the U.S. FDA by year end 2015. The FDA will evaluate adding these data to the current labeling for Vyvanse, according to a Shire media release.
    • 22 Jul 2015 Top-line results were published in the Shire Media Release.
    • 27 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top